Event Brief
FDA approves once-daily PCSK9 pill Lipfendra
Filed: Jul 16, 2026 at 10:04 AM ET
Summary: Lipfendra, a once-daily oral PCSK9 inhibitor, received FDA approval after cutting LDL by about 56% to 60% with statins.
WHO: FDA
WHAT: FDA approval of Lipfendra, a once-daily oral PCSK9 inhibitor shown to reduce LDL cholesterol by roughly 56% to 60% with statins.
WHEN: Jul 16, 2026 at 9:35 AM ET
WHERE: USA
WHY: The FDA approved Lipfendra after clinical results showed it reduced LDL cholesterol by roughly 56% to 60% when combined with statins.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
🔍 10 sources analyzed
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →